Wen Chen has served as a board member of Taris since 2017. He is the Senior Vice President of Tigermed Co. Ltd. a publicly traded company located in China. Tigermed is a leading Contract Research Organization in China and Asia Pacific dedicated to provide professional clinical development services to the pharmaceutical and medical device industries. Wen represents Yonghua Capital, a leading private equity and venture capital investment firm from China that has invested in Taris. Wen received a Bachelor’s Degree in Biochemistry from Purdue University, West Lafayette, IN and a Master’s Degree in Immunology and Oncology and Business Administration from Washington University in St. Louis and Durham University respectively. He then worked at Amgen research before returning to work in China biotechnology industry since 2000.